Loading...

Proteostasis Therapeutics

DB:42P
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
42P
DB
$61M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The last earnings update was 41 days ago. More info.


Add to Portfolio Compare Print
  • Proteostasis Therapeutics has significant price volatility in the past 3 months.
42P Share Price and Events
7 Day Returns
-9%
DB:42P
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-73.4%
DB:42P
-9.2%
DE Biotechs
-6.7%
DE Market
42P Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Proteostasis Therapeutics (42P) -9% -69.8% -60% -73.4% -86.5% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 42P underperformed the Biotechs industry which returned -9.2% over the past year.
  • 42P underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
42P
Industry
5yr Volatility vs Market
Related Companies

42P Value

 Is Proteostasis Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Proteostasis Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Proteostasis Therapeutics.

DB:42P Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.1%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:42P
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (23.27%))
1.485
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.48
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.485 * 5.96%)
9.08%

Discounted Cash Flow Calculation for DB:42P using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Proteostasis Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:42P DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.08%)
2019 -84.00 Analyst x1 -77.01
2020 -106.00 Analyst x1 -89.09
2021 91.00 Analyst x1 70.12
2022 68.00 Analyst x1 48.04
2023 52.00 Analyst x1 33.68
2024 42.32 Est @ -18.61% 25.13
2025 36.84 Est @ -12.96% 20.05
2026 33.52 Est @ -9% 16.73
2027 31.43 Est @ -6.23% 14.38
2028 30.08 Est @ -4.3% 12.62
Present value of next 10 years cash flows $74.63
DB:42P DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $30.08 × (1 + 0.23%) ÷ (9.08% – 0.23%)
$340.69
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $340.69 ÷ (1 + 9.08%)10
$142.89
DB:42P Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $74.63 + $142.89
$217.52
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $217.52 / 51.04
$4.26
DB:42P Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:42P represents 0.91x of NasdaqGM:PTI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.91x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 4.26 x 0.91
€3.88
Value per share (EUR) From above. €3.88
Current discount Discount to share price of €1.09
= -1 x (€1.09 - €3.88) / €3.88
71.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Proteostasis Therapeutics is available for.
Intrinsic value
>50%
Share price is €1.09 vs Future cash flow value of €3.88
Current Discount Checks
For Proteostasis Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Proteostasis Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Proteostasis Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Proteostasis Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Proteostasis Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:42P PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.61
NasdaqGM:PTI Share Price ** NasdaqGM (2019-04-18) in USD $1.2
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Proteostasis Therapeutics.

DB:42P PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PTI Share Price ÷ EPS (both in USD)

= 1.2 ÷ -1.61

-0.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Proteostasis Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Proteostasis Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Proteostasis Therapeutics's expected growth come at a high price?
Raw Data
DB:42P PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
40.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Proteostasis Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Proteostasis Therapeutics's assets?
Raw Data
DB:42P PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.25
NasdaqGM:PTI Share Price * NasdaqGM (2019-04-18) in USD $1.2
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:42P PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PTI Share Price ÷ Book Value per Share (both in USD)

= 1.2 ÷ 2.25

0.53x

* Primary Listing of Proteostasis Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Proteostasis Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Proteostasis Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Proteostasis Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

42P Future Performance

 How is Proteostasis Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Proteostasis Therapeutics expected to grow at an attractive rate?
  • Proteostasis Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Proteostasis Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Proteostasis Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:42P Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:42P Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 40.8%
DB:42P Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 49.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:42P Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:42P Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 43 52 1
2022-12-31 3 68 1
2021-12-31 3 91 1
2020-12-31 3 -101 -106 1
2019-12-31 1 -81 -82 3
DB:42P Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -59 -62
2018-09-30 4 -51 -58
2018-06-30 5 -50 -54
2018-03-31 5 -49 -55
2017-12-31 5 -52 -59
2017-09-30 8 -55 -55
2017-06-30 8 -54 -52
2017-03-31 8 -49 -44
2016-12-31 8 -42 -39
2016-09-30 6 -34 -37
2016-06-30 5 -28 -36
2016-03-31 5 -23 -27

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Proteostasis Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Proteostasis Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:42P Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42P Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 -1.74 -1.74 -1.74 1.00
2019-12-31 -1.64 -1.54 -1.74 2.00
DB:42P Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.61
2018-09-30 -1.75
2018-06-30 -1.77
2018-03-31 -1.99
2017-12-31 -2.34
2017-09-30 -2.21
2017-06-30 -2.20
2017-03-31 -1.99
2016-12-31 -2.06
2016-09-30 -2.94
2016-06-30 -4.60
2016-03-31 -8.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Proteostasis Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Proteostasis Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Proteostasis Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

42P Past Performance

  How has Proteostasis Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Proteostasis Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Proteostasis Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Proteostasis Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Proteostasis Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Proteostasis Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:42P Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.84 -61.83 18.11 47.92
2018-09-30 4.46 -58.36 17.35 46.30
2018-06-30 4.96 -53.88 15.88 43.67
2018-03-31 5.26 -55.36 15.28 45.98
2017-12-31 5.34 -59.43 14.61 50.70
2017-09-30 7.78 -55.43 15.79 48.05
2017-06-30 7.94 -52.24 15.77 44.93
2017-03-31 8.25 -44.34 14.99 37.95
2016-12-31 8.38 -38.61 13.39 32.45
2016-09-30 5.56 -37.13 12.38 27.36
2016-06-30 5.04 -35.70 10.63 24.40
2016-03-31 4.66 -26.58 9.23 22.97
2015-12-31 4.31 -23.31 8.25 20.60
2015-09-30 4.39 -22.07 7.26 20.22
2015-03-31 4.94 -30.17 6.23 15.94
2014-12-31 5.15 -29.65 6.03 14.80
2013-12-31 1.14 -22.61 5.99 10.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Proteostasis Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Proteostasis Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Proteostasis Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Proteostasis Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Proteostasis Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

42P Health

 How is Proteostasis Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Proteostasis Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Proteostasis Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Proteostasis Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Proteostasis Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 8.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Proteostasis Therapeutics Company Filings, last reported 3 months ago.

DB:42P Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 114.34 14.25 118.38
2018-09-30 38.91 14.50 46.40
2018-06-30 56.33 14.75 60.82
2018-03-31 60.13 15.67 63.33
2017-12-31 68.81 0.56 74.46
2017-09-30 38.32 0.00 43.23
2017-06-30 51.16 0.00 57.70
2017-03-31 67.09 0.00 70.17
2016-12-31 81.46 0.00 85.51
2016-09-30 89.97 0.00 100.24
2016-06-30 30.61 0.00 42.64
2016-03-31 39.53 0.00 49.81
2015-12-31 4.30 0.00 13.84
2015-09-30 9.69 0.00 20.92
2015-03-31 -13.35 10.40 4.30
2014-12-31 -8.11 10.20 8.79
2013-12-31 2.20 0.00 2.59
  • Proteostasis Therapeutics's level of debt (12.5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.3% vs 12.5% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Proteostasis Therapeutics has sufficient cash runway for 2 years based on current free cash flow.
  • Proteostasis Therapeutics has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 26.9% each year.
X
Financial health checks
We assess Proteostasis Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Proteostasis Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

42P Dividends

 What is Proteostasis Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Proteostasis Therapeutics dividends.
If you bought €2,000 of Proteostasis Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Proteostasis Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Proteostasis Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:42P Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:42P Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Proteostasis Therapeutics has not reported any payouts.
  • Unable to verify if Proteostasis Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Proteostasis Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Proteostasis Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Proteostasis Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Proteostasis Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Proteostasis Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

42P Management

 What is the CEO of Proteostasis Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Meenu Chhabra
COMPENSATION $1,783,730
AGE 46
TENURE AS CEO 4.9 years
CEO Bio

Ms. Meenu Chhabra has been the Chief Executive Officer and President at Proteostasis Therapeutics, Inc. since May, 2014. Ms. Chhabra's initial focus is driving the development of Proteostasis' cystic fibrosis franchise while leveraging its platform to identify pipeline appropriate assets addressing orphan and neurodegenerative disease indications. She has extensive managerial experience in the biopharmaceutical industry with a strong track record of corporate execution. Prior to joining Proteostasis, Ms. Chhabra served as the Chief Executive Officer and President of Allozyne Inc. from August 2007 to May 2014. While at Allozyne, she implemented a strategy to maximize the value of the proprietary platform by building a portfolio of risk reward balanced product candidates including antibody drug conjugates. Ms. Chhabra served as the Chief Business Officer of BioXell S.p.A. from July 2003 to November 2006. She served as Vice President, Business Development and Licensing for Novartis Consumer Health (Geneva, Switzerland) and Novartis AG from December 2006 to August 2007. Ms. Chhabra joined BioXell in September 2003 as Director of Business Development and Commercial Strategy. Prior to BioXell, Ms. Chhabra held various sales, marketing and business development positions in major pharmaceutical companies (most notably, Bristol Myers Squibb Inc., Parke Davis/Warner Lambert and Fresenius Kabi AG). Previously, Ms. Chhabra served as Business Development Manager at MCR Research Inc. Prior to joining MCR, she served as a Business Development Manager at Fresenius Kabi Healthcare. She has been a Director of Allozyne, Inc. since October 2007 and Proteostasis Therapeutics, Inc. since May, 2014. Ms. Chhabra holds a Bachelor of Science degree from University of Toronto in Pharmacology and Master's in Business Administration from York University with a focus in Strategy and Finance.

CEO Compensation
  • Meenu's compensation has increased whilst company is loss making.
  • Meenu's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Proteostasis Therapeutics management team in years:

0.7
Average Tenure
49
Average Age
  • The average tenure for the Proteostasis Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Meenu Chhabra

TITLE
President
COMPENSATION
$2M
AGE
46
TENURE
4.9 yrs

Ben Munoz

TITLE
Chief Scientific Officer
COMPENSATION
$715K
AGE
56
TENURE
2.1 yrs

Po-Shun Lee

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$783K
AGE
49
TENURE
3.9 yrs

Sandra Zimmerman

TITLE
VP of Finance
TENURE
0.7 yrs

Sheila Wilson

TITLE
Chief Operating Officer
TENURE
0.2 yrs

Geoffrey Gilmartin

TITLE
Chief Medical Affairs Officer
AGE
50
TENURE
0.2 yrs

Masha Zecevic

TITLE
Chief Commercial Officer
AGE
44
TENURE
0.2 yrs

Jeffrey Held

TITLE
General Counsel & Secretary

Claudia Styslinger

TITLE
Investor Relations Executive
Board of Directors Tenure

Average tenure and age of the Proteostasis Therapeutics board of directors in years:

3.2
Average Tenure
58
Average Age
  • The tenure for the Proteostasis Therapeutics board of directors is about average.
Board of Directors

Jim Barrett

TITLE
Chairman of the Board
COMPENSATION
$156K
AGE
76
TENURE
2.8 yrs

Meenu Chhabra

TITLE
President
COMPENSATION
$2M
AGE
46
TENURE
4.9 yrs

Jeffery Kelly

TITLE
Director & Member of Scientific Advisory Board
COMPENSATION
$180K
AGE
58
TENURE
12.3 yrs

F. Hartl

TITLE
Chairman of Scientific Advisory Board

Richard Moss

TITLE
Chairman of Clinical Advisory Board

Franklin Berger

TITLE
Director
COMPENSATION
$139K
AGE
69
TENURE
3.2 yrs

Kim Drapkin

TITLE
Director
AGE
50
TENURE
0.2 yrs

Bill Morimoto

TITLE
Member of Scientific Advisory Board

Daniel Finley

TITLE
Member of Scientific Advisory Board

Randall King

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
26. Oct 18 Buy Franklin Berger Individual 26. Oct 18 26. Oct 18 40,000 €5.93 €237,195
X
Management checks
We assess Proteostasis Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Proteostasis Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

42P News

Simply Wall St News

42P Company Info

Description

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company’s lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. It has a collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

Details
Name: Proteostasis Therapeutics, Inc.
42P
Exchange: DB
Founded: 2006
$54,486,877
51,040,615
Website: http://www.proteostasis.com
Address: Proteostasis Therapeutics, Inc.
80 Guest Street,
Suite 500,
Boston,
Massachusetts, 02135,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PTI Common Stock Nasdaq Global Market US USD 11. Feb 2016
DB 42P Common Stock Deutsche Boerse AG DE EUR 11. Feb 2016
Number of employees
Current staff
Staff numbers
49
Proteostasis Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:23
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/08
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.